Ivantis, Inc.

After its spin-out from Novartis AG in 2019, ophthalmology specialist Alcon Inc. has steadily expanded its pharmaceutical portfolio and formed a dedicated sales channel to focus specifically on ey

Alcon is making an aggressive return to the minimally invasive glaucoma surgery market by acquiring Ivantis for at least $475m, the companies announced on 8 November. Ivantis markets Hydrus Microst

Many glaucoma patients who have cataract surgery to reduce intraocular pressure (IOP) often receive a stent – a tiny device implanted in the eye’s drainage channel to help restore the natural flow of

San Clemente, California-based Glaukos Corp. reported a 22% net sales growth reaching $65.8m in the fourth quarter of 2019, but cautioned that rising competition in the microinvasive glaucoma surger